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The lncRNA NRON modulates HIV-1
replication in a NFAT-dependent manner
and is differentially regulated by early
and late viral proteins
Hasan Imam, Aalia Shahr Bano, Paresh Patel, Prasida Holla & Shahid Jameel*
Virology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
A majority of the human genome is transcribed into noncoding RNAs, of which the functions of long
noncoding RNAs (lncRNAs) are poorly understood. Many host proteins and RNAs have been characterized
for their roles in HIV/AIDS pathogenesis, but there is only one lncRNA, NEAT1, which is shown to affect
the HIV-1 life cycle. We profiled 90 disease-related lncRNAs and found NRON (noncoding repressor of
Nuclear Factor of Activated T cells [NFAT]) to be one of several lncRNAswhose expressionwas significantly
altered following HIV-1 infection. The regulation of NRON expression during the HIV-1 life cycle was
complex; its levels were reduced by the early viral accessory protein Nef and increased by the late protein
Vpu. Consequently, Nef and Vpu alsomodulated activity of the transcription factor NFAT. The knockdown
of NRON enhanced HIV-1 replication through increased activity of NFAT and the viral LTR. Using
siRNA-mediated NFAT knockdown, we show the effects of NRON on HIV-1 replication to be mediated by
NFAT, and the viral Nef andVpu proteins tomodulateNFAT activity through their effects onNRON.These
findings add the lncRNA, NRON to the vast repertoire of host factors utilized by HIV for infection and
persistence.
I
t is estimated that only 2% of the human genome codes for proteins, but over 70% of it is transcribed into
RNA1. The protein-noncoding RNAs (ncRNAs) are divided into small ncRNAs (,200 nt) and long non-
coding RNAs (lncRNAs) (.200 nt) based on their size1. The lncRNAs are important epigenetic regulators
whose roles in disease processes are being increasingly recognized2. The possible mechanisms involved in
lncRNA-mediated regulation include: translational modulation of mRNAs following sequence-specific recog-
nition; targeting of chromatin modifiers to DNA through the formation of RNA-DNA hybrids; RNA secondary
structure mediated targeting and sequestration of host factors; and as scaffolds to recruit multiple proteins into
functional ribonucleoprotein complexes3. A recent annotation of lncRNAs produced by the human genome puts
the number at 9277 genes and 14,880 transcripts4.While the small ncRNAs, especially themicroRNAs (miRNAs)
have been studied extensively for their roles in regulating gene expression during development and disease,
studies on lncRNAs are limited. Although the pivotal role of individual lncRNAs in development and disease is
being increasingly realized5, their possible roles in the pathogenesis of infectious disease have not received similar
attention6.
The human immunodeficiency virus type 1 (HIV-1) contains nine genes that include the prototypic gag, pol
and env, the regulatory tat and rev, and the accessory nef, vif, vpr and vpu genes7. For its replication, HIV-1 also
utilizes a vast array of host factors8, while some host proteins such as APOBEC3G, BST2, etc., and miRNAs
restrict viral replication9–11. To overcome intrinsic host restriction, HIV-1 accessory proteins such as Nef, Vif and
Vpu play important and interesting roles12. Several reports also show the differential expression of host and viral
miRNAs during HIV infection13–15, and host miRNAs to be predictive biomarkers of HIV/AIDS disease pro-
gression16. Despite rich literature on the interaction between HIV-1 and host factors, including miRNAs, there is
only one published report on the role of endogenous lncRNAs in HIV-1 biology. Zhang et al profiled lncRNAs
modulated in T-cell lines following HIV-1 infection, and characterized NEAT1 for its role in modulating post-
transcriptional regulation of HIV-1 expression17.
To further study the relationship betweenHIV-1 and lncRNAs, we have profiled 90 disease-related lncRNAs in
two human T-cell line models, and found several of these lncRNAs to be modulated following HIV-1 infection
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and replication. In this report, we show the lncRNA NRON to be
downregulated in HIV-1 infected T cell lines and the viral accessory
proteins Nef and Vpu to reciprocally regulate NRON levels. We
further show that NRON modulates HIV-1 replication through its
effects on the nuclear factor of activated T cells (NFAT).
Results
HIV-1 infection reduces NRON expression levels. To investigate if
the expression of lncRNAs is altered byHIV-1 infection, we looked at
90 lncRNAs implicated in various diseases, including multiple
cancers. Two cellular models were used, which included infection
of the human Jurkat T-cell line with HIV-1, and J1.1 cells following
PMA activation. The latter are Jurkat cells latently infected with
HIV-1 and show robust viral replication and gene expression on
activation with phorbol esters. From these two diverse yet related
systems, we identified several lncRNAs that were modulated during
HIV-1 infection and replication (Fig. 1A). The selection criteria
included at least two-fold upregulation or downregulation, a p-value
of , 0.05 and a qRT-PCR threshold cycle (CT) value of , 35. Based
on these analyses, we found 2 lncRNAs (GAS5 family and NRON) to
be downregulated and 21 lncRNAs to be upregulated in HIV-1-
infected compared to mock-infected Jurkat cells. When compared to
mock-activated cells, the PMA-activated J1.1 cells showed 4 lncRNAs
(Emx2os, GAS5 family, NRON and Zfas1) to be downregulated and
23 lncRNAs to be upregulated. We found 2 downregulated and 18
upregulated lncRNAs to be common between the two cellular systems
(Fig. 1B). An earlier study found the lncRNA NEAT1 to be upregu-
lated in HIV infected Jurkat cells17. While we also found NEAT1 levels
to increase, these were only 1.26-fold and 2.12-fold higher in HIV
infected Jurkat cells and PMA activated J1.1 cells, respectively.
Among the identified lncRNAs, we pursued NRON because its
expression was consistently downregulated the most in both experi-
mental models. Further, NRON is a noncoding repressor of the tran-
scription factor NFAT, which enhances HIV-1 gene expression in
primary CD4 T cells18,19. We confirmed our profiling data by infect-
ing Jurkat cells with HIV-1 NL4-3 at 1 moi for 48 hr and quantified
NRON expression by semi-quantitative RT-PCR. Compared to mock-
infected cells, HIV-1 infected Jurkat cells showed,40% lower NRON
levels (Fig 1C).
The HIV-1 accessory proteins Nef and Vpu reciprocally regulate
NRON levels and NFAT activity. We then carried out a kinetic
assessment of the effects of HIV-1 infection on NRON in Jurkat
cells and in U937 cells, which is a human monocytic cell line. We
further tested whether the HIV-1 Nef accessory protein, which is
expressed early during infection, might have a role in modulating
NRON levels. Jurkat (Fig. 2A) or U937 (Fig. 2B) cells were infected
with HIV-1 NL4-3 or a Nef-deficient variant, NL4-3DNef, and
NRON levels were quantified at different times post-infection by
qRT-PCR. At 12 hr post-infection (hpi), NRON levels go down in
both cell types compared to mock-infected cells. Infection with Nef-
deficient viruses did not show this decrease, but showed higher
NRON levels. There were significant increases in NRON levels at
24 hpi, and these reduced substantially at 48 hpi. Nef was sufficiently
expressed between 12 to 48 hpi, whereas the Vpu accessory protein
started expressing at 24 hpi and attained good levels by 48 hpi. The
results presented in Fig. 2A and 2B were normalized to mock-
infected cells, which displayed stable NRON levels during this time
period. Such complex regulation suggests that NRON levels might be
regulated by more than one HIV-1 protein. Therefore, we used
single-gene expression or knockout systems to tease out the effects
of Nef and Vpu on NRON.
In U937 cells that stably expressed a Nef-EYFP fusion protein, we
found reduced NRON levels compared to cells that expressed only
EYFP (Fig. 2C). However, in U937 cells that stably expressed a Vpu-
GFP fusion protein, the NRON levels were elevated (Fig. 2D). As
earlier, U937 cells infected with HIV-1 NL4-3DNef also showed
higher NRON levels than those infected with the full virus; there
was reduced viral replication in cells infected with NL4-3DNef, as
seen from p24Gag levels (Fig. S1A). Analogous to this, infection of
U937 (Fig. S1B) or Jurkat (Fig. S1C) cells with the NL4-3 and NL4-
3DVpu viruses showed reduced NRON levels in the absence of Vpu.
These results clearly show that while the Nef protein decreases
NRON levels, the Vpu protein increased these.
We then mined next generation sequencing (NGS) data available
with us from U937/Vpu-GFP and U937/GFP cells (P. Patel et al;
unpublished). The Integrated Genome Viewer (IGV) image (Fig.
S2) showed sequence coverage in the NRON region, and differential
expression of NRON was calculated using CuffDiff on three repli-
cates. In agreement with qRT-PCR, the NGS results also showed
increased expression of NRON in Vpu-expressing cells (Fig. 3A).
Match Analysis of coding sequences provided lists of transcription
factors whose sites were over-represented in either upregulated (not
shown) or downregulated (Fig. 3B) coding sequences in Vpu-expres-
sing cells. Interestingly, NFAT binding sites were over-represented in
the upstream regions of genes that are downregulated inVpu-expres-
sing cells (Fig. 3B). To confirm this, we transfected U937/Vpu-GFP
(or U937/GFP) and U937/Nef-EYFP (or U937/EYFP) stable cell
lines with the NFAT-Luc reporter plasmid, and quantified luciferase
activity in the cell lysates. There was reduced NFAT promoter activ-
ity in Vpu-expressing cells (Fig. 3C) and increased activity in Nef-
expressing cells (Fig. 3D). Thus, analogous to their effects on NRON
levels, Nef and Vpu reciprocally affect NFAT activity as well.
NRON modulates HIV-1 replication through NFAT-mediated
effects on the viral LTR. The experiments described above revealed
the effects of HIV-1 infection and replication on cellular NRON levels.
Since NRON represses the activity of NFAT, which is an impor-
tant factor in activated T cells that promotes HIV-1 replication, it is
also likely to influence the replication of HIV-1. To address this, we
employed a short hairpin RNA (shRNA) to establish stable NRON
knockdown lines in Jurkat cells. Control Jurkat cell lines were also
established using a scrambled shRNA. Based on semi-quantitative RT-
PCR (Fig. S3A) and qRT-PCR (Fig.S3B), the shNRON Jurkat cells
showed 40–50% lower NRON levels compared to the scrambled
shRNA control cells.
We then asked if HIV-1 replication rates were different in NRON
knockdown and control Jurkat cells. For this, both cell lines were
infected with 1 moi of HIV-1 NL4-3, and the cells and supernatants
were harvested at 12, 24, 36 and 48 hpi. The cell lysates and super-
natants were checked for Gag expression; equal volumes of the cell
supernatants were also subjected to the TZMbl assay to estimate
infectious virions released from the cells. At each time point, the
NRON knockdown Jurkat cells produced more Gag (p55, p24 and
intermediate forms) protein compared to the control cells (Fig. 4A).
Importantly, at all time points the amounts of infectious virions
produced per unit volume of culture supernatants were higher for
NRON knockdown Jurkat cells compared to control cells (Fig. 4B).
The transcription factor NFAT is responsive to local changes in
intracellular calcium and is crucial for the T-cell receptor-mediated
immune response20. The stimulation of HEK293 cells with PMA/
ionomycin, or shRNA-mediated knockdown of the NRON lncRNA
was shown to result in increased NFAT activity19. We observed the
same in Jurkat cells knocked down for NRON by transfecting the
NFAT-luc reporter plasmid; these cells showed about 40% higher
NFAT activity compared to control cells (Fig. 4C).
The HIV-1 LTR has multiple binding sites for lymphoid specific
transcription factors and employs these for activation dependent
viral gene expression21. NFAT is one such factor with two sets of
binding sites identified in the HIV-1 LTR promoter that overlap the
NFkB binding sites18. Since increased NFAT levels should also trans-
late into increased HIV-1 LTR activity, we tested for this with trans-
www.nature.com/scientificreports
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Figure 1 | Differential expression of lncRNAs in HIV-1 infected cells. (A) Profiling results from Jurkat cells infected with HIV-1 NL4-3 (top) and J1.1
cells following PMA treatment (bottom). The plots show relative fold expression compared to control cells for three replicates. The dotted lines indicate
the selected 2-fold cut-off. (B) Venn diagram summarizing the profiling results in the two experimental systems. The lncRNAs marked in bold were
downregulated while others were upregulated. (C) Validation of NRON downregulation in HIV-1 NL4-3 infected Jurkat cells at 48 hpi by semi-
quantitative RT-PCR. A representative cropped gel image is shown forNRONandActin RNAswhere the semi-quantitative RT-PCRproducts were run in
a 2% agarose gel in same experimental condition. The full images are shown in Fig. S7A. The plot shows densitometry of gels from three separate
experiments shown as mean values 6 SD; * p,0.05.
www.nature.com/scientificreports
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fection of an LTR-luc reporter plasmid. As expected, higher HIV-1
LTR activity was observed in NRON knockdown Jurkat cells com-
pared to control cells (Fig. 4D).
To further confirm that NRON regulates HIV-1 replication
through its effects on NFAT, we carried out siRNA-mediated knock-
down of NFAT in the background of control or NRON knockdown
Jurkat cells. To establish knockdown efficiency, we first transfected
HEK293T cells with either an NFAT-specific siRNA or a control
non-targeting siRNA, and followed this up by transfection of the
NFAT-luc reporter plasmid. There was reduced NFAT activity in
cells that received the NFAT siRNA compared to the control siRNA
(Fig. S3C). This was then repeated in the control or NRON knock-
down Jurkat cell lines with the same results (Fig. S3D). Finally, we
evaluated HIV-1 replication in these cells by western blotting for
p55Gag and p24CA in cell lysates and for new virions (p24CA) in culture
supernatants. Cells knocked down for NRON showed increased Gag
expression (Fig. 4E; lanes 1 and 3), as observed earlier (Fig. 4A), and
is due to higher levels of NFAT. Cells receiving the NFAT siRNA
showed reduced Gag expression (Fig. 4E; lanes 1 and 2) since func-
tional NFAT is reduced in these cells through the siRNA as well as
NRON. However, NRON knockdown cells that received the NFAT
siRNA showed relatively higher levels of Gag (Fig. 4E; lanes 2 and 4)
because functional NFAT in these cells is reduced only through the
siRNA. There was a severe reduction in intracellular Gag levels and
Figure 2 | HIV-1 Nef and Vpu reciprocally regulate NRON expression. (A) Relative NRON expression levels at different times after infection of Jurkat
cells with 1moi of HIV-1NL4-3 andHIV-1NL4-3DNef viruses. The NRON levels were estimated by quantitative RT-PCR, were normalized to Actin and
are expressed relative to levels found in mock-infected Jurkat cells. The cropped western blots show Nef and Vpu expression at different times after
infection with HIV-1 NL4-3, with Actin as a loading control; the full images for these are shown in Fig. S7B. (B) Relative NRON expression levels at
different times after infection of U937 cells with 1 moi of HIV-1 NL4-3 and HIV-1 NL4-3DNef viruses. The NRON levels were estimated by quantitative
RT-PCR, were normalized to actin and are expressed relative to levels found inmock-infected U937 cells. (C) NRON expression levels in U937 cells stably
expressing the Nef-EYFP fusion protein compared to cells stably expressing EYFP, at 48 hr after plating. (D) NRON expression levels in U937 stably
expressing the Vpu-GFP fusion protein compared to cells stably expressing GFP, at 48 hr after plating. Results from three separate experiments are shown
as mean values 6 SD; * p,0.05.
www.nature.com/scientificreports
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secreted virus on NFAT knockdown, but this recovered significantly
when the NFAT reduction was in the NRON knockdown back-
ground (Fig. S4A). This was also true for gag RNA (Fig. S4B).
The lncRNANRON binds to NFAT and inhibits its nuclear trans-
location. We activated control or NRON knockdown cells with
PMA/Ionomycin and tested for NFAT levels in whole cell lysates,
nuclear and cytoplasmic fractions by western blotting (Fig. S5). We
also stained cells for NFAT and quantified the signals and its colo-
calization with the nuclear marker DAPI (Fig. S6). NFAT levels were
higher in NRON knockdown cells compared to control cells (Fig.
S5A). This was also the case with nuclear levels of NFAT, which
increased further on activation (Fig. S5B). Fluorescent imaging and
quantification of NFAT (Fig. S6) agreed with the fractionation and
western blotting results, showing increased nuclear translocation of
NFAT in NRON knockdown cells. Together, these results support
our hypothesis that themodulation ofHIV-1 replication byNRON is
mediated through NFAT.
The effects of HIV-1 on NFAT activity are directed through
NRON. Previously we showed that Nef decreased NRON levels
and Vpu increased these. Further, these HIV-1 proteins reciprocally
altered NFAT activity as well, with Nef increasing it and Vpu
decreasing it. To prove that the NFAT activity changes were due to
varying NRON levels, we first co-transfected HEK293T cells with the
infectious HIV-1 plasmids pNL4-3, pNL4-3DVpu or pNL4-3DNef,
together with the shNRON (or control shRNA) plasmid and the
NFAT-luc reporter plasmid. The NFAT activity was always higher in
the NRON knockdown background when wild type or Vpu-deficient
HIV-1 was present, but was lower in the case of Nef-deficient HIV-1
(Fig. 5A, B). The same experiment was then repeated in Jurkat cells that
Figure 3 | HIV-1 Nef and Vpu reciprocally modulate NFAT activity. (A) Expression levels of NRON RNA in U937 cells stably expressing Vpu-GFP
compared to those in U937 cells stably expressing GFP deduced from RNA-Seq data. (B) Graphical representation of Match Analysis of NGS data as
described in Methods. The transcription factor binding sites that are over-represented in downregulated coding sequences (CDS) are shown; arrow
indicates NFAT. (C)NormalizedNFAT-Luc activity inU937 cells stably expressing the Vpu-GFP fusion protein compared to cells expressing onlyGFP, at
48 hr after plating. (D) Normalized NFAT-Luc activity in U937 cells stably expressing the Nef-EYFP fusion protein compared to cells expressing only
EYFP, at 48 hr after plating. Results from three separate experiments are shown as mean values 6 SD. * p,0.05.
www.nature.com/scientificreports
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were stably knocked down for NRON. In this case, one of the three
infectious HIV-1 plasmids was nucleofected in NRON knockdown
(or control) Jurkat cells together with the NFAT-luc reporter plasmid.
Again, NFAT activity was higher in the NRON knockdown back-
ground, except when Nef-deficient HIV-1 was used (Fig. 5C, D).
These results show that during viral infection, the Nef and Vpu
proteins regulate NFAT activity by modulating NRON expression.
Discussion
We report here only the second example in literature for lncRNA
involvement in HIV-1 replication. Our profiling studies showed
HIV-1 infection to significantly reduce the intracellular levels of
NRON in two human T-cell line models of infection. Interestingly,
the HIV-1 accessory Nef protein, which is expressed early in the viral
life cycle reduced NRON levels, but the accessory Vpu protein
expressed late in replication, increased NRON levels. Jurkat cells
stably knocked down for NRON expression also showed increased
HIV-1 replication.
On comparing our study with that of Zhang et al17, we note that
NRON was not part of their lncRNA array. Like that study, we also
observed NEAT1 to be upregulated in HIV-1 infected cell models, but
the increases had borderline significance. A close scrutiny showed the
GAS5 family lncRNAs to be downregulated in both studies and the
following lncRNAs to be upregulated: Air, antiPeg11, CAR intergenic
Figure 4 | NRONmodulates HIV-1 replication through NFAT-mediated LTR activation. (A) Control (lanes C) or NRON (lanes N) knockdown Jurkat
cells were infected with 1 moi of HIV-1 NL4-3 and harvested at different times post-infection. Cropped western blot shows p55Gag and p24Gag in cell
lysates, with Actin as a loading control; the full image is shown in Fig. S7C. (B) The graph shows results of TZMbl assay of corresponding supernatants of
cells in (A). Data were normalized with the luciferase reading of control knockdown cells. (C) NFAT activity in NRON knockdown cells compared to
control knockdown cells, estimated by transfection of pNFAT-luc reporter plasmid, at 48 hr post-transfection. (D) HIV-1 LTR activity in NRON
knockdown cells compared to control knockdown cells, estimated by transfection of pHIV-luc reporter plasmid, at 48 hr post-transfection. The Firefly
luciferase readings were divided by Renilla luciferase readings to normalize for transfection efficiency as described in Methods. (E) Effects on HIV-1
replication of NFAT knockdown in control and NRON knockdown cellular backgrounds. The NFAT siRNA transfections and analyses at 48 hr post-
transfection were carried out as described inMethods. Cropped western blot (full image in Fig. S7D) shows p55Gag and p24Gag in cell lysates, and p24Gag in
supernatants. Actin served as a loading control for cell lysates. For quantitation, results from three separate experiments are shown as mean values 6 SD;
* p,0.05.
www.nature.com/scientificreports
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10, EgoB, HOTAIR, HOTAIRM1, HOX3AS, KRASP1, lincRNA-p21,
LOC285194, LUST, MEG9, ncR-uPAR, PSF inh RNA, SRA, ST7OT,
Tmevpg1 and Zeb2NAT. Some common themes emerge from the
known functions of these lncRNAs22 that might be of relevance
to HIV-1 infection and persistence. The GAS5 family, KRASP1,
lincRNA-p21 and LUST lncRNAs are responsible for reduced growth
arrest and apoptosis, and increased cell proliferation, which positively
impacts HIV-1 infection and replication. At least four lncRNAs – Air,
HOTAIR, antiPeg11 and MEG9 are involved in epigenetic silencing,
of which HOTAIR and antiPeg11 bind and recruit the polycomb
repressor complex 2 (PRC2). It was shown earlier that PRC2-mediated
silencing is important for HIV-1 latency23. The lncRNA Tmevpg1 is
expressed in NK, CD41 and CD81 cells, and cross-regulates gamma
interferon24, which is an important proinflammatory cytokine during
HIV infection. Interestingly, HIV also encodes an antisense lncRNA
that regulates viral transcription by altering the epigenetic landscape at
the viral promoter25.
The lncRNA NRON is about 2.7 kb in length and is composed of
three exons, which can be alternatively spliced to yield transcripts
ranging in size from 0.8 to 3.7 kb19. It was identified as a noncoding
RNA repressor of the transcription factor NFAT, which regulated the
nuclear trafficking of NFAT19. The NFAT family has five members,
NFAT1 to NFAT5, of which all except NFAT5 are calcium regulated
transcription factors, and NFAT1 is the predominant family member
expressed in primary human CD4 T cells26. In resting T cells, NFATs
are phosphorylated and retained in cytoplasm by the NRON complex27.
Following calcium stimulation, NFAT proteins are dephosphorylated
by the Ca21/calmodulin-dependent phosphatase, Calcineurin, and
translocate to the nucleus to activate gene expression28. The NFAT
proteins bind the NFkB sites in the HIV-1 LTR, and NFAT1 and
NFAT2 were shown to increase HIV-1 transcription and replication
in primary human CD4 T cells and Jurkat cells29,30. As a non-coding
repressor of NFAT, the lncRNA NRON may also modulate HIV tran-
scription and replication. Indeed, our results show that knockdown of
NRON in Jurkat cells leads to increased NFAT activity, HIV-1 LTR
activity and HIV-1 replication.
The Nef protein is expressed very early following HIV-1 infection,
and is reported to have multiple activities that promote viral replica-
Figure 5 | HIV-1 Nef and Vpu alter NFAT activity through their effects on NRON. (A) NFAT activity in (A) HEK293T cells transfected with plasmids
pNL4-3 or pNL4-3DVpu together with either control shRNA or NRON shRNA plasmids, and the NFAT-luc reporter plasmid; (B) HEK293T cells
transfected with plasmids pNL4-3 or pNL4-3DNef together with either control shRNA or NRON shRNA plasmids, and the NFAT-luc reporter
plasmid; (C) Control or NRON knockdown Jurkat cells transfected with plasmids pNL4-3 or pNL4-3DVpu and the NFAT-luc reporter plasmid; and
(D) Control or NRON knockdown Jurkat cells transfected with plasmids pNL4-3 or pNL4-3DNef and the NFAT-luc reporter plasmid. Transfections
and luciferase estimations were carried out as described inMethods. All measurements were made at 48 hr post-transfection. Results from three separate
experiments are shown as mean values 6 SD; * p,0.05.
www.nature.com/scientificreports
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tion. This includes its ability to coordinate T cell activation through
synergistic activation of the calcium/calcineurin and Ras-Raf-MAPK
signaling pathways and induction of NFAT31. In the absence of fur-
ther stimulation, HIV replication in CD41 T lymphocytes is sup-
ported by the overexpression of NFAT target genes like IL-2 and
FasL32. Additionally, NFAT proteins interact with the NF-kB
responsive element and activate HIV-1 LTR directed transcription32.
We confirmed these effects of Nef on NFAT and showed these to be
mediated by NRON expression. We also made the novel observation
that Vpu, which is expressed late in HIV-1 infection, decreases
NFAT activity by increasing NRON levels. Thus, NRON appears
to act as a rheostat that finely tunes the degree of T-cell activation
and HIV-1 LTR mediated transcription by controlling NFAT activ-
ity. This is likely to be important for maintaining a balance between
viral replication and activation-mediated T-cell death.
Our approach and findings are summarized in themodel shown in
Figure 6. The replication of HIV-1 in CD41 T cells or the expression
of Nef results in reduced NRON levels, leading to NFAT activation
and increased transcription from theHIV-1 LTR. This, together with
NFAT-mediated T-cell activation, has an overall positive effect on
HIV-1 replication. Later in the viral life cycle, the late accessory Vpu
protein increases NRON levels, possibly attenuating T-cell activation
and death. Exactly how Nef and Vpu modulate NRON expression
levels remains an interesting question to be addressed in future
studies.
Methods
Plasmids and antibodies. The pNL4-3, pNL4-3DNef and pNL4-3DVpu infectious
molecular clones of HIV-1 subtype B were obtained from the NIH AIDS Research
and Reagent Program (NIAID, Rockville, MD, USA). The NFAT-Luc (#17870)
reporter plasmid was obtained fromAddgene (deposited by Dr. Gerry Crabtree), and
the LTR-Luc reporter plasmid was from Dr. Akhil Banerjea, National Institute of
Immunology, New Delhi, India. The scrambled shRNA and NRON-specific shRNA
sequences were cloned in the pSIREN-Retro Q-Zs green1 vector33. The NRON
shRNA sequence19 was as follows: Forward oligo 59-GATCCGCTGTTTCCACTA-
CTGCTCCTTCAAGAGAGGAGCAGTAGTGGAAACAG TTTTTTCTAGAG-39,
Reverse oligo 59-AATTCTCTAGAAAAAAACTGTTTCCACTACT GCTCCTCT-
CTTGAAGGAGCAGTAGTGGAAACAGCG-39. Anti-p24 (hybridoma sup) was
from the NIH AIDS Research and Reagent Program (NIAID, Rockville, MD, USA),
anti-Histone, anti-GAPDH and anti-Actin antibodies were from Santa Cruz
Biotechnology (USA), anti-NFAT antibody was from Abcam (UK), anti-mouse IgG-
HRP was from Calbiochem (USA) and Alexa Fluor488 and Alexa Fluor594
conjugated secondary antibodies was from Molecular Probes (Invitrogen, USA).
LncRNA profiling.HIV-1 was produced in HEK293T cells transfected with plasmid
pNL4-3; the culture supernatants were harvested 48 hr post-transfection and
infectious titers were estimated on TZMbl cells34. For lncRNA profiling, Jurkat cells
were infected with HIV-1 at 1.0 moi and J1.1 cells were activated with 50 ng/ml
phorbol 12-myristate 13-actetate (PMA). Two days later, culture supernatants and
cells were harvested and western blotting for p24 was used to check viral replication.
Total RNA was extracted from cells using Trizol reagent (Invitrogen), following the
manufacturer’s instructions. The same amounts of RNA were converted to cDNA
and the Human LncRNA Profiler Array kit (System Biosciences) was used to profile
lncRNAs in the samples according to the manufacturer’s instructions. The 90
lncRNAs profiled were as follows: 21A, 7SK, 7SL, Air, AK023948, Alpha 280, Alpha
250, ANRIL, anti-NOS2A, antiPeg11, BACE1AS (family), BC200, CAR Intergenic 10,
DHFR upstream transcripts (family), Dio3os (family), DISC2 (family), DLG2AS
(family), E2F4 antisense, EgoA, EgoB, Emx2os, Evf1 and EVF2, GAS5-family,
Gomafu, H19, H19 antisense, H19 upstream conserved 1 & 2, HAR1A, HAR1B,
HOTAIR, HOTAIRM1, HOTTIP, Hoxa11as, HOXA3as, HOXA6as, HULC, IGF2AS
(family), IPW, Jpx, Kcnq1ot1, KRASP1, L1PA16, lincRNA-p21, lncRNA-RoR,
lincRNA-SFMBT2, lincRNA-VLDLR, LOC285194, LUST, Malat1, mascRNA,
MEG3 (family), MEG9, MER11C, ncR-uPAR, NDM29, NEAT1 (family), Nespas,
NRON,NTT, p53mRNA, PCGEM1, PR antisense transcripts, PRINS, PSF inhibiting
RNA, PTENP1, RNCR3, SAF, SCA8, snaR, SNHG1, SNHG3, SNHG4, SNHG5,
SNHG6, Sox2ot, SRA, ST7OT, TEA ncRNAs (family), Tmevpg1, TncRNA, Tsix,
TUG1 (family), UCA1, UM9-5, WT1-AS, Xist, Y RNA-1, Zeb2NAT, Zfas1 and
Zfhx2as. TheMIHS excel format (Qiagen, Germany) was used for analysis of the PCR
array data. In this analysis, Ct values .35 were automatically excluded and four
endogenous controls (GAPDH, 18S rRNA, U6 snRNA and RNU43) were considered
in the analysis. The output included fold changes in the corresponding lncRNAs in
HIV-1 infected or PMA activated cells with respect to the control cells, and the p
values for these changes.
Cell culture, transfection and infection. The stable cell lines U937/Vpu-GFP, U937/
GFP, U937/Nef-EYFP andU937/EYFP have been described elsewhere35,36. These cells
as well as Jurkat and J1.1 cells37 (obtained from NIH AIDS Research and Reagent
Program; NIAID, Rockville, MD, USA) were maintained in RPMI 1640
supplemented with 10% fetal bovine serum (FBS). The TZMbl and HEK293T cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS.
Plasmids were transfected into HEK293T cells using jetPRIME reagent (Polyplus
Transfection Co., USA). For transfection into Jurkat cells, 2 million cells were
suspended in 100 ml of Solution V (Nucleofector kit V; Amaxa Biosystems) and
mixed with 4 mg plasmids or 50 nM siRNAs, and processed following the
manufacturer’s instructions. The Nef- and Vpu-defective viruses were produced and
tittered as described above for HIV-1. All infections were carried out at 1.0 moi.
RNA inhibition. To prepare shRNA stable lines, plasmids containing the NRON or
control shRNA (6 mg) were transfected into 2 million HEK293T cells along with
plasmids pVSV-g (1.5 mg) and pGag-Pol (3 mg). The culture supernatants were
collected after 48 hr, filtered through 0.45 mm filters and 10 ml was used to directly
infect 5 million Jurkat cells. After 48 hr, cells expressing GFP were sorted out at the
Stem Cell Biology Lab, National Institute of Immunology (New Delhi, India) and
thereafter maintained in RPMI 1640 containing 10% FBS. For siRNA-mediated
knockdown of NFAT, the ON-TARGET plus Human NFATC1 siRNA SMART pool
Figure 6 | Proposed model for cross-regulation of NRON and HIV-1 replication. The model shows HIV-1 infection and the viral Nef protein to reduce
NRON levels, and the viral Vpu protein to increase NRON levels. This in turn regulates activity of the transcription factor NFAT, which enhances
transcription from the HIV-1 LTR. The interventions with shRNA-mediated NRON knockdown and siRNA-mediated NFAT reduction, are shown.
www.nature.com/scientificreports
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(4772) (Thermo Fisher Scientific, Lafayette, USA) was used; the ON-TARGET plus
Non-targeting siRNA#1 (D-001810-01-20) was used as the scrambled control.
NGS andMatch Analysis. The RNA from U937/Vpu-GFP (and control U937/GFP)
stable cell lines was sequenced at the Center for Cellular and Molecular Platforms (c-
CAMP), Bengaluru, India. The paired end RNA-seq was performed on Illumina-
HiSeq 1000 with the insert size of around 140-200 bases. The kits used for sample
preparation were TruSeq RNA sample preparation kit RS-122-2001 and RS-122-
2002. For Cluster generation, TruSeq PE Cluster Kit V3, and for sequencing the FC-
401-3001-TruSeq SBS Kit V3-HS were used. Differential expression analysis was
performed using TopHat (http://ccb.jhu.edu/software/tophat/index.shtml) and
Cufflinks packages at the default settings (http://cufflinks.cbcb.umd.edu/). The
MATCH program (http://www.biobase-international.com/product/explain) was
used to scan the 2500 to 1100 nucleotides in the promoter regions of differentially
regulated coding sequences (CDS) using collections of known transcription factor
binding site (TFBS) and positional weight matrices, to identify binding sites for a
given transcription factor in the upregulated or downregulated CDS. Promoters from
human housekeeping genes were taken as a control set.
Semi-quantitative and quantitative PCR.ThemiScript II RT kit (Qiagen, Germany)
was used to prepare cDNA and quantitative PCR was done with SYBR green master
mix (Solis BioDyne, Estonia) using the following primers: NRON forward, 59-
ACGTTCCTTAATGTACGCCTTTGC-39, NRON reverse, 59-TTGGCCGTGTCC-
TGAGTC CTT-39; Actin forward, 59-TGGCGCTTTTGACTCAGGAT-39, Actin
reverse, 59-GTTACT ACCCAGGTCAGGCCAG-39; Gag forward, 59-ACCCATG-
TTTCAGCATTAT-39, Gag reverse 59-GCTTGATGTCCCCCTACTGT-39. The
qRT-PCR program was 95uC for 10 min followed by 40 cycles at 95uC for 30 sec,
60uC for 30 sec, 72uC for 30 sec, and fold changes in gene expression were calculated
by the DDCT method. For semi-quantitative PCR, the program was 95uC for 1 min
followed by 25 cycles at 95uC for 30 sec, 60uC for 30 sec and 72uC for 30 sec, and fold
changes in gene expression were calculated based on densitometry using the NIH
Image J software to determine band intensities.
Western blotting.Cell pellets were washed twice with ice-cold PBS and lysed with 1X
SDS protein loading buffer (50 mM Tris, 2% SDS, 10% glycerol, 2% b-
mercaptoethanol, and 0.1% bromophenol blue). The samples were boiled at 95uC for
5 min and clarified lysates were resolved by SDS-10%-PAGE and transferred to
polyvinylidene fluoride (PVDF) membranes (MDI, Karnal, India). The membrane
was blocked with 5% BSA for 1 hour, followed by overnight incubation with primary
antibodies (151000) diluted in 2% BSA. After washing, the membranes were
incubated with HRP-conjugated secondary antibodies (155000) for 1 hour. The
signals were detected using a chemiluminescence substrate (Santa Cruz
Biotechnology, USA). The NIH Image J software was used for blot densitometry.
TZMbl assay. The TZMbl cells were seeded in the wells of a 96-well plate (10,000
cells/well) with complete DMEM. On the next day, medium was removed from each
well and cells were washed once with 200 ml incomplete DMEM. Cells were starved
for 1 hr in 100 ml incomplete DMEM, which was then removed and different
dilutions of virus were added in a total volume of 100 ml of incomplete DMEM. After
4–6 hr of incubation at 37uC in a 5% CO2 incubator, the virus containing medium
was removed and 100 ml of complete medium was added. After 48 hr of incubation,
the luciferase reading was taken using Steady-Glo luciferase assay reagent according
to manufacturer’s instructions (Promega, Madison, USA).
Luciferase assay. Cells were transfected with the Firefly luciferase reporters as
described above together with plasmid pRLTK that constitutively expresses Renilla
luciferase. Cell lysates were assayed for Firefly and Renilla luciferase activities using
the Dual Luciferase Assay System (Promega, Madison, USA) as per manufacturer’s
instructions. All Firefly luciferase readings were divided by Renilla luciferase readings
to normalize for transfection efficiency of cells.
Cell fractionation. Control and NRON knockdown cells were stimulated for 3 hr
with 5 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma) and 1.5 ug/ml
Ionomycin (Sigma). For preparation of cytoplasmic and nuclear fractions, the
harvested cells were lysed in Triton X-100 lysis buffer (50 mM Tris HCl (pH 7.5),
0.5% Triton X-100, 137.5 mM NaCl, 10% glycerol, 1 mM sodium vanadate, 50 mM
sodium fluoride, 10 mM sodium pyrophosphate, 5 mM EDTA and protease
inhibitor cocktail) on ice for 15 min. The mixture was then centrifuged at 3000 rpm
for 5 min at 4uC in a microfuge. The supernatant was saved as the cytoplasmic
fraction. The pellet was resuspended in equal volume of Triton X-100 lysis buffer and
centrifuged at 13000 rpm for 15 min at 4uC in amicrofuge; the supernatant served as
the nuclear fraction. The protein levels were estimated using the Bradford assay
(BioRad) and equal amounts of total proteins were western blotted. Histone H1 and
GAPDH served as nuclear and cytoplasmic markers, respectively.
NFAT microscopy and quantification. For immunofluorescence staining, control
and NRON knockdown stable Jurkat cells were activated with PMA/Ionomycin for
6 hr, washed, fixed with 2% paraformaldehyde for 10 min and treated with the
permeabilization buffer (Perkin Elmer, USA). Cells were then blocked with 5% BSA,
incubated with anti-NFAT antibody (15500 in 1%BSA solution) for 1 hr, followed by
Alexa Fluor594 conjugated anti-mouse secondary antibody (151500 in 1% BSA
solution) for 1 hr. Cells were then mounted on glass slides with Prolong Gold
DAPI1antifade solution (Life Technologies, USA) and visualized on a Nikon A1R
laser scanning confocal microscope. Fluorescence intensity measurements and image
processing were carried out using NIS Elements microscope imaging software.
Statistical analyses. Analyses of the lncRNA, NGS, quantitative and semi-
qunatitative PCRdatawere carried out as detailed in the respective sections. Statistical
significance was calculated by paired two-tailed T Test and p,0.05 was considered
significant.
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